BioNTech Hosts Innovation Series Day

TL;DR

BioNTech's Innovation Series Day is today, Nov 14, with updates on their pipeline.

AI Summary

On November 14, 2024, BioNTech SE is holding its Innovation Series Day, presenting updates on its pipeline and strategic initiatives. The details of this event are attached as Exhibit 99.1 to the filing.

Why It Matters

This event provides investors and the public with insights into BioNTech's ongoing research and development, potentially impacting future growth and stock valuation.

Risk Assessment

Risk Level: low — The filing is an informational update about an event, not a financial disclosure with significant new risks.

Key Players & Entities

• BioNTech SE (company) — Registrant
• November 14, 2024 (date) — Date of Innovation Series Day

FAQ

From the Filing

0001776985-24-000096.txt : 20241114 0001776985-24-000096.hdr.sgml : 20241114 20241114073846 ACCESSION NUMBER: 0001776985-24-000096 CONFORMED SUBMISSION TYPE: 6-K PUBLIC DOCUMENT COUNT: 113 CONFORMED PERIOD OF REPORT: 20241114 FILED AS OF DATE: 20241114 DATE AS OF CHANGE: 20241114 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BioNTech SE CENTRAL INDEX KEY: 0001776985 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: 2M FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 6-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39081 FILM NUMBER: 241457225 BUSINESS ADDRESS: STREET 1: AN DER GOLDGRUBE 12 CITY: MAINZ STATE: 2M ZIP: 55131 BUSINESS PHONE: 0049613190840 MAIL ADDRESS: STREET 1: AN DER GOLDGRUBE 12 CITY: MAINZ STATE: 2M ZIP: 55131 6-K 1 form6-kinnovationseriesday.htm 6-K Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a‑16 OR 15d‑16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF NOVEMBER 2024 COMMISSION FILE NUMBER 001-39081 BioNTech SE (Translation of registrant’s name into English) An der Goldgrube 12 D-55131 Mainz Germany +49 6131-9084-0 (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover Form 20‑F or Form 40‑F: Form 20‑F ☒ Form 40‑F ☐ Indicate by check mark if the registrant is submitting the Form 6‑K in paper as permitted by Regulation S‑T Rule 101(b)(1): ☐ Indicate by check mark if the registrant is submitting the Form 6‑K in paper as permitted by Regulation S‑T Rule 101(b)(7): ☐ DOCUMENTS INCLUDED AS PART OF THIS FORM 6-K On November 14, 2024, BioNTech SE is hosting an edition of its Innovation Series Day. The presentation is attached as Exhibit 99.1. SIGNATURE Pursuant to the requirements of the Exchange Act, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. BioNTech SE By: /s/ Jens Holstein By: /s/ Dr. Sierk Poetting Name: Jens Holstein Name: Dr. Sierk Poetting Title: Chief Financial Officer Title: Chief Operating Officer Date: November 14, 2024 EXHIBIT INDEX Exhibit Description of Exhibit 99.1 Presentation EX-99.1 2 a99_1innovationday2024de.htm EX-99.1 a99_1innovationday2024de Innovation Series 2024 November 14, 2024 10:30 AM – 2:15 PM ET Exhibit 99.1 1 Welcome & Introductory Remarks Ryan Richardson, Chief Strategy Officer This Slide Presentation Includes Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, but not limited to, statements concerning: BioNTech’s expected revenues and net profit/(loss), particularly for those figures that are derived from preliminary estimates provided by BioNTech’s partners; the rate and degree of market acceptance of BioNTech’s COVID-19 vaccine and, if approved, BioNTech’s investigational medicines; expectations regarding anticipated changes in COVID-19 vaccine demand, including changes to the ordering environment and expected regulatory recommendations to adapt vaccines to address new variants or sublineages; the initiation, timing, progress, results, and cost of BioNTech’s research and development programs, including BioNTech’s current and future preclinical studies and clinical trials, including statements regarding the expected timing of initiation, enrollment, and completion of studies or trials and related preparatory work and the availability of results, and the timing and outcome of applications for regulatory approvals and marketing authorizations; BioNTech’s expectations regarding potential future comme